Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)
Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –
Halozyme Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Halozyme Therapeutics's total debt was $2.15B at Jun 30, 2026. For fiscal 2025 it was $2.14B, up 42.3% from the year before. Over ten years it grew 45.7% a year on average. The highest annual figure on record is $2.14B in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.14B | +42.3% |
| FY2024 | Dec 31, 2024 | $1.51B | +0.4% |
| FY2023 | Dec 31, 2023 | $1.50B | -0.5% |
| FY2022 | Dec 31, 2022 | $1.51B | +71.8% |
| FY2021 | Dec 31, 2021 | $876.67M | +120.7% |
| FY2020 | Dec 31, 2020 | $397.23M | -1.3% |
| FY2019 | Dec 31, 2019 | $402.59M | +218.6% |
| FY2018 | Dec 31, 2018 | $126.38M | -37.5% |
| FY2017 | Dec 31, 2017 | $202.35M | -6.6% |
| FY2016 | Dec 31, 2016 | $216.62M | +334.7% |
| FY2015 | Dec 31, 2015 | $49.83M | -0.1% |
| FY2014 | Dec 31, 2014 | $49.86M | +0.2% |
| FY2013 | Dec 31, 2013 | $49.77M | +67.8% |
| FY2012 | Dec 31, 2012 | $29.66M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.15B | +42.2% |
| Q1 FY2026 | Mar 31, 2026 | $2.14B | +42.3% |
| Q4 FY2025 | Dec 31, 2025 | $2.14B | +42.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.51B | +0.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.51B | +0.4% |
| Q1 FY2025 | Mar 31, 2025 | $1.51B | +0.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.51B | +0.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.50B | +0.4% |
| Q2 FY2024 | Jun 30, 2024 | $1.50B | +0.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.50B | +0.4% |
| Q4 FY2023 | Dec 31, 2023 | $1.50B | -0.5% |
| Q3 FY2023 | Sep 30, 2023 | $1.50B | -0.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.50B | +1410.4% |
| Q1 FY2023 | Mar 31, 2023 | $1.49B | +1568.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.51B | +71.8% |
| Q3 FY2022 | Sep 30, 2022 | $1.50B | +1585.7% |
| Q2 FY2022 | Jun 30, 2022 | $99.05M | +11.1% |
| Q1 FY2022 | Mar 31, 2022 | $89.55M | +0.6% |
| Q4 FY2021 | Dec 31, 2021 | $876.67M | +120.7% |
| Q3 FY2021 | Sep 30, 2021 | $89.25M | – |
| Q2 FY2021 | Jun 30, 2021 | $89.17M | – |
| Q1 FY2021 | Mar 31, 2021 | $89.04M | +3014.4% |
| Q4 FY2020 | Dec 31, 2020 | $397.23M | -1.3% |
| Q3 FY2020 | Sep 30, 2020 | $0 | -100.0% |
| Q2 FY2020 | Jun 30, 2020 | $0 | -100.0% |
| Q1 FY2020 | Mar 31, 2020 | $2.86M | -96.7% |
| Q4 FY2019 | Dec 31, 2019 | $402.59M | +218.6% |
| Q3 FY2019 | Sep 30, 2019 | $54.54M | -38.4% |
| Q2 FY2019 | Jun 30, 2019 | $70.88M | -18.5% |
| Q1 FY2019 | Mar 31, 2019 | $86.66M | +5.1% |
| Q4 FY2018 | Dec 31, 2018 | $126.38M | -37.5% |
| Q3 FY2018 | Sep 30, 2018 | $88.52M | +44.1% |
| Q2 FY2018 | Jun 30, 2018 | $86.97M | +91.1% |
| Q1 FY2018 | Mar 31, 2018 | $82.46M | +178.6% |
| Q4 FY2017 | Dec 31, 2017 | $202.35M | -6.6% |
| Q3 FY2017 | Sep 30, 2017 | $61.43M | +395.7% |
| Q2 FY2017 | Jun 30, 2017 | $45.52M | – |
| Q1 FY2017 | Mar 31, 2017 | $29.60M | – |
| Q4 FY2016 | Dec 31, 2016 | $216.62M | – |
| Q3 FY2016 | Sep 30, 2016 | $12.39M | – |
See a number that looks wrong?